- Version
- Download 0
- File Size 4.00 KB
- File Count 1
- Create Date August 7, 2026
- Last Updated August 7, 2026
From Genomics to Therapy: Emerging Biomarkers and Targets in Oncology 2025/2026
Prof. Shaheenah Dawood explores the rapidly evolving landscape of precision oncology, highlighting how emerging genomic and immune biomarkers are reshaping treatment selection and enabling increasingly personalized therapy across multiple cancer types.
In this forward-looking session, Prof. Shaheenah Dawood examines how advances in molecular profiling are transforming oncology from a one-size-fits-all approach to truly individualized cancer care. The presentation introduces the principles of precision medicine and demonstrates how genomic and immune biomarkers can guide treatment selection, predict therapeutic benefit, and identify patients most likely to respond to targeted therapies and immunotherapy.
The session reviews the expanding biomarker landscape in advanced cancers, emphasizing that clinically relevant alterations now extend beyond single-gene mutations to include broader genomic signatures, tumour-immune interactions, and emerging resistance pathways.
Prof. Dawood also addresses the practical implementation of precision oncology within routine clinical practice, including optimal patient selection for molecular testing, interpretation of complex genomic reports, management of co-occurring alterations, and integration of molecular findings within multidisciplinary tumour boards. The session highlights current challenges such as tumour heterogeneity, clonal evolution, resistance mechanisms, limited tissue availability, and disparities in biomarker accessibility, while outlining future directions involving liquid biopsy, serial molecular monitoring, AI-assisted genomic interpretation, and adaptive precision medicine strategies.
Importantly, the presentation highlights the practical challenge of translating rapidly evolving molecular discoveries into meaningful treatment decisions. By connecting biomarker identification with therapeutic actionability, this session provides clinicians with a contemporary framework for applying precision oncology in 2025/2026 and underscores the growing role of comprehensive genomic testing in tailoring therapy to the biology of each patient’s tumour.
<iframe width="1840" height="1035" src="https://www.youtube.com/embed/PXhCY8q46vk" title="" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
